Schering-Plough has licensed to ViroDefense the exclusive rights for development of a specific compound series for polio indications. The license was provided in exchange for the purchase of compound testing supplies and potential future royalties on sales.
ViroDefense claims that the lead anti-poliovirus compound, V-073, has been shown to have potent and broad-spectrum anti-poliovirus specific activity, favorable pharmacologic and pharmacokinetic attributes, and the safety and tolerability profile suitable for its advancement as a preclinical candidate. Consequently, IND-enabling studies will commence with V-073.
Marc Collett, president of ViroDefense, said: “We are grateful to Schering-Plough for their willingness to offer this promising antiviral series for the fight against polio. This is clearly a humanitarian gesture on their part.”